ARS Pharmaceuticals, Inc.

NASDAQ:SPRY

Biotechnology

Healthcare
$3.69 -3.51%

-$0.35 today

Market cap
$370.95M
Beta
0.83
P/E (TTM)
-4.8
EPS (TTM)
-$1.99
52W Low $6.66High $18.90

Volume 1.70M

Average 1.67M

SPRY Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

ARS Pharmaceuticals, Inc.NASDAQ: SPRY

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 72.3%

Gross margin was 72.3% in Q1 FY2026, up 23.0 pp from a year earlier. On a trailing-twelve-month basis it was 77.1%, down 7.5 pp year over year. Over 3 fiscal years it widened by 1276.7 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
72.3%-16.3 pp QoQ
Last fiscal yearDec 2025
75.8%-1.2 pp YoY
LTMMar 2026
77.1%-7.5 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+23.0 pp——
1 year-1.2 pp——
3 years+1276.7 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
75.8%
Year-over-year change
-1.2pp

Gross Margin vs competitors

How SPRY compares with its peers on the latest reported figures

  • SPRY's LTM Mar 2026 gross margin of 77.1% is the 2nd highest of the 4 companies compared; the peer median is 76.0%.
  • Its year-over-year change of -7.5 pp is the lowest of 4, against a peer median of +0.6 pp.
  • Over three fiscal years its change of +1276.7 pp compares with a peer median of +2.2 pp.
SPRY Competitors Peer median
Gross Margin for SPRY and competitors
Company Period LTM level YoY 3-year change
XERSXeris Biopharma Holdings, Inc.LTM Mar 202681.6% +0.6 pp+2.2 pp
SPRYARS Pharmaceuticals, Inc.LTM Mar 202677.1% -7.5 pp+1276.7 pp
MNKDMannKind CorporationLTM Mar 202676.0% +1.3 pp+40.1 pp
AQSTAquestive Therapeutics, Inc.LTM Mar 202663.5% -4.9 pp+2.1 pp
Peer median (excluding SPRY) 76.0%+0.6 pp+2.2 pp

Competitors are the stored peer set for SPRY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5.51M1.32M30K89.15M84.28M
Cost of Revenue213K17.12M020.56M20.42M
Gross Profit5.29M(15.8M)30K68.59M63.86M
Gross Margin96.1%-1200.9%100.0%76.9%75.8%
Research & Development20.27M18.38M20.27M19.58M13.18M
Selling, General & Admin4.69M18.66M47.28M0230.12M
Operating Expenses24.75M19.71M67.55M71.68M243.3M
Depreciation & Amortization213K319K73K79K1.37M
EBITDA(19.92M)(34.36M)(54.29M)8.37M(167.41M)
EBITDA Margin-361.9%-2611.2%-180973.3%9.4%-198.6%
Operating Income(19.45M)(35.52M)(67.52M)(3.08M)(179.45M)
Operating Margin-353.3%-2698.8%-225066.7%-3.5%-212.9%
Interest Income800K00010.67M
Interest Expense106K0002.6M
Other Income / Expenses(789K)834K13.16M11.37M8.07M
Income Before Tax(20.24M)(34.68M)(54.37M)8.29M(171.38M)
Pre-Tax Margin-367.7%-2635.4%-181216.7%9.3%-203.3%
Income Tax Expense000288K(80K)
Net Income(20.24M)(34.68M)(54.37M)8M(171.3M)
Net Margin-367.7%-2635.4%-181216.7%9.0%-203.3%
EPS (Basic)(0.70)(0.87)(0.57)0.08(1.74)
EPS (Diluted)(0.70)(0.87)(0.57)0.08(1.74)
Weighted Avg Shares28.87M39.96M95.22M96.94M98.57M
Weighted Avg Shares (Diluted)28.87M39.96M95.22M102.39M98.57M

ARS Pharmaceuticals, Inc.

NASDAQ:SPRY

Intrinsic Alpha fair value

Locked

Current Price

$3.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.